Table of Contents
<< Previous Issue | Sept 2020 (Vol: 2020, Issue: 9) | Next Issue >> |
- Section: Licensing
-
Sanofi Delves Further into Protein Degrader Therapies with US$2.33 B Kymera Deal
- Section: Mergers & Acquisitions
-
Gilead Continues Immuno-oncology Spree with US$21 B Immunomedics Buy
- Section: Opinion & Analysis
-
IQVIA Pharma Deals Half-Year Review of 2020
- Section: Research & Development
-
Merck Signs Two Oncology Collaborations with Seattle Genetics